References
- Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomized, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. DOI:10.1016/S0140-6736(16)31275-2
- Wilkinson D, Windfeld K, Colding-Jørgensen E. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomized double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2014;13:1092–1099.
- Hendrix JA, Bateman RJ, Brashear HR, et al. Challenges, solutions and recommendations for Alzheimer’s disease combination therapy. Alz Dement. 2016;12:623–630.
- Tomaszewski S, Gauthier S, Wimo A, et al. Combination therapy of anti-tau and anti-amyloid drugs for disease modification in early-stage Alzheimer’s disease: socio-economic considerations modeled on treatments for tuberculosis, HIV/AIDS and breast cancer. J Prev Alz Dis. 2016;3:164–172.
- Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimer’s Dement. 2016;12:110–120.
- Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces aß plaques in Alzheimer’s disease. Nature. 2016;537:50–56. DOI:10.1038/nature19323
- Kennedy ME, Stamford AW, Chen X, et al. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS ß-amyloid in animal models and in Alzheimer’s disease patients. Sci Transl Med. 2016;8:363ra150.
- Berr C. Primary prevention of dementia: an epidemiological point of view. J Prev Alz Dis. 2016;3:160–163.
- Langa KM, Larson EB, Crimmins EM, et al. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med. 2016. DOI:10.1001/jamainternmed.2016.6807
- Dolgin E. How to defeat dementia. Nature. 2016;539:156–158.